https://www.selleckchem.com/pr....oducts/bozitinib.htm
8 months (95% CI [73.3-90.3]). Thirty-six patients (60%) achieved a 3-year follow-up time; the mortality rate was 15% at the end of the study. Age superior to 65 years and transformation into DLBCL were statistically significant negative prognostic markers for survival in this study (p = 0.006 and p = 0.033, respectively). Our study confirms that gMALT NHL is an indolent disease with long-term survival. Many patients, however, are exposed to several treatment lines along their disease course. Flow cytometric (FCM) immunophenotyping is
Gefällt mir
Kommentar
Teilen
